CoChat

Successful treatment of a novel type I interferonopathy due to a de novo PSMB9 gene mutation with a Janus kinase inhibitor

Open access
Kataoka, Shinsuke, Kawashima, Nozomu, Okuno, Yusuke, Muramatsu, Hideki, Miwata, Shunsuke, Narita, Kotaro, Hamada, Motoharu, Murakami, Norihiro, Taniguchi, Rieko, Ichikawa, Daisuke, Kitazawa, Hironobu, Suzuki, Kyogo, Nishikawa, Eri, Narita, Atsushi, Nishio, Nobuhiro, Yamamoto, Hidenori, Fukasawa, Yoshie, Kato, Taichi, Yamamoto, Hiroyuki, Natsume, Jun, Kojima, Seiji, Nishino, Ichizo, Taketani, Takeshi, Ohnishi, Hidenori, Takahashi, Yoshiyuki · 2021 · Journal of Allergy and Clinical Immunology
Cited by 43

The DOI matches its Crossref record.

Abstract

BACKGROUND Type I interferonopathies are a recently established subgroup of autoinflammatory diseases caused by mutations in genes associated with proteasome degradation or cytoplasmic RNA and DNA sensing pathways. OBJECTIVE This study aimed to unveil the molecular pathogenesis of a patient with novel type I interferonopathy, for which no known genetic mutations have been identified. METHODS We performed the whole exome sequencing (WES) of a 1-month-old boy with novel type I interferonopathy. We also investigated proteasome activities using patient-derived B lymphoblastoid cell lines (LCLs) and normal LCLs transduced with the mutant gene. RESULTS WES identified a de novo proteasome 20S subunit beta 9 (PSMB9) p.G156D mutation in the patient who developed fever, a chilblain-like skin rash, myositis, and severe pulmonary hypertension due to the hyperactivation of interferon-alpha. Patient-derived LCLs revealed reduced proteasome activities, and exogenous transduction of mutant PSMB9 p.G156D into normal LCLs significantly suppressed proteasome activities, and the endogenous PSMB9 protein was lost along with the reduction of other immunoproteasome subunits, PSMB8 and PSMB10 proteins. He responded to the administration of a Janus kinase (JAK) inhibitor, tofacitinib, and he was successfully withdrawn from veno-arterial extracorporeal membranous oxygenation. At 7 months of age, he received an unrelated cord blood transplantation. At 2 years post transplantation, he no longer required tofacitinib and experienced no disease recurrence. CONCLUSION We present the case of a patient with a novel type I interferonopathy caused by a de novo PSMB9 p.G156D mutation which suppressed the wild-type PSMB9 protein expression. JAK inhibitor and stem cell transplantation could be curative therapies in patients with severe interferonopathies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2021.03.010

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 43

Metadata

Authors
Kataoka, S., Kawashima, N., Okuno, Y., Muramatsu, H., Miwata, S., Narita, K., Hamada, M., Murakami, N., Taniguchi, R., Ichikawa, D., Kitazawa, H., Suzuki, K., Nishikawa, E., Narita, A., Nishio, N., Yamamoto, H., Fukasawa, Y., Kato, T., Yamamoto, H., Natsume, J., Kojima, S., Nishino, I., Taketani, T., Ohnishi, H., & Takahashi, Y.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2021-08
Volume
148
Issue
2
Pages
639-644
ISSN
0091-6749 (ISSN-L)
OpenAlex
W3136824607
Cited by
43
References
0
FWCI
2.23
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Successful treatment of a novel type I interferonopathy due to a de novo PSMB9 gene mutation with a Janus kinase inhibitor. https://app.cochat.ai/papers/10.1016/j.jaci.2021.03.010
The paper
Kataoka, S., Kawashima, N., Okuno, Y., Muramatsu, H., Miwata, S., Narita, K., Hamada, M., Murakami, N., Taniguchi, R., Ichikawa, D., Kitazawa, H., Suzuki, K., Nishikawa, E., Narita, A., Nishio, N., Yamamoto, H., Fukasawa, Y., Kato, T., Yamamoto, H., . . . Takahashi, Y. (2021). Successful treatment of a novel type I interferonopathy due to a de novo PSMB9 gene mutation with a Janus kinase inhibitor. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2021.03.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.